Alterity Therapeutics
ATHE
13 hedge funds and large institutions have $416K invested in Alterity Therapeutics in 2024 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 2 reducing their positions, and 3 closing their positions.
180% more capital invested
Capital invested by funds: $149K → $416K (+$267K)
0% more funds holding
Funds holding: 13 → 13 (0)
0% more ownership
Funds ownership: 0% → 0% (+0%)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$51.8K |
| 2 |
BNP Paribas Financial Markets
Paris,
France
|
+$14K |
| 3 |
HWM
HB Wealth Management
Atlanta,
Georgia
|
+$12.9K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
+$159 |
| 5 |
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
|
+$25 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$19.5K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$18.7K |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$15.4K |
| 4 |
PCA
Providence Capital Advisors
Charlotte,
North Carolina
|
-$263 |
| 5 |
Morgan Stanley
New York
|
-$159 |
ATHE Hedge Fund Activity: Q4 2024 in Review
13 of the 7,602 institutional investors tracked by Wall St. Rank reported a position in Alterity Therapeutics (ATHE) for Q4 2024, worth a combined $416K — up 180% from $149K a quarter earlier.
Fund positioning in ATHE was balanced in Q4 2024: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 2 trimmed.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $51.8K. The largest seller was UBS Group, cutting an estimated $19.5K.
- 13 institutional investors held Alterity Therapeutics (ATHE) as of Q4 2024, unchanged from Q3 2024.
- Funds reported $416K of Alterity Therapeutics stock for Q4 2024, up 180% quarter-over-quarter.
- 3 funds opened new Alterity Therapeutics positions in Q4 2024 and 3 closed out, a net change of 0 holders.
- The largest Alterity Therapeutics buyer in Q4 2024 was Point72 Asset Management, an estimated $51.8K added.
- The largest Alterity Therapeutics seller in Q4 2024 was UBS Group, an estimated $19.5K sold.
Based on aggregated 13F filings for Q4 2024.